ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 777

Effect of Certolizumab Pegol On Signs and Symptoms of Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 24 Week Results of a Double Blind Randomized Placebo-Controlled Phase 3 Axial Spondyloarthritis Study

Robert B. M. Landewé1, Martin Rudwaleit2, Désirée van der Heijde3, Maxime Dougados4, Walter P. Maksymowych5, Jürgen Braun6, Atul A. Deodhar7, Christian Stach8, Bengt Hoepken8, Geoffroy Coteur9, Danuta Kielar9, Andreas Fichtner8, Terri Arledge10 and Joachim Sieper11, 1Academic Medical Center/University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, 2Endokrinologikum Berlin, Berlin, Germany, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 4Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, 5Department of Medicine, University of Alberta, Edmonton, AB, Canada, 6Rheumazentrum Ruhrgebiet, Herne, Germany, 7Oregon Health & Science University, Portland, OR, 8UCB Pharma, Monheim am Rheim, Germany, 9UCB Pharma, Brussels, Belgium, 10UCB Pharma, Rtp, NC, 11Medical Department I, Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), anti-TNF therapy, certolizumab pegol and spondylarthropathy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment: Spondyloarthritis I

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Axial spondyloarthritis (axSpA ) includes both ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA), as defined by the ASAS criteria.1 RAPID-axSpA (NCT01087762) is the first report of certolizumab pegol (CZP), a PEGylated Fc-free anti-TNF, in axSpA, and the first randomized controlled trial of an anti-TNF to include the entire axSpA population.

Methods:

The ongoing 158 week (wk) RAPID-axSpA trial is double-blind and placebo (PBO) controlled to Wk24, dose-blind to Wk48 and then open label to Wk158. Recruited patients (pts) had adult-onset active axSpA as defined by the ASAS criteria,1 BASDAI ≥4, spinal pain ≥4 on a 10 point scale, CRP > upper limit of normal or sacroillitis on MRI. Pts must have failed ≥1 NSAID. Up to 40% of pts could have experienced secondary failure to 1 previous anti-TNF. The pt population reflected the broad axSpA population, including AS pts meeting the modified New York criteria and nr-axSpA pts who met the ASAS MRI or clinical criteria. Pts were randomized 1:1:1 to PBO, or 400mg CZP at Wk 0, 2 and 4 (loading dose, LD) followed by either 200mg CZP every 2 wks (Q2W) or 400mg CZP every 4 wks (Q4W). Pts receiving PBO who failed to achieve an ASAS20 response at both Wks 14 and 16 were rescued and randomized at Wk16 to receive CZP 200mg Q2W or CZP 400mg Q4W following LD. The primary endpoint was ASAS20 response at Wk12. Non-responder imputation was used for ASAS responses; last observation carried forward was used for BASFI, BASMI and BASDAI.

Results:

325 pts were randomized. Baseline (BL) characteristics were similar between treatment groups (PBO/CZP 200 mg Q2W/CZP 400 mg Q4W) with the exception of higher CRP concentrations, and greater proportion of anti-TNF experienced pts in the PBO group (25.4/17.4/21.2 mg/L; 24.3%/13.5%/10.3%, respectively). AS pts had longer disease and symptom duration at BL compared to nr-axSpA pts. Clinical improvements in ASAS20 responses at Wk12 were statistically significant in CZP 200 mg Q2W and CZP 400 mg Q4W arms vs PBO (Table) and were observed as early as Wk1 (40.5% and 34.6% vs 14.2%, p<0.001). ASAS40 response and ASAS partial remission rates were also higher in the CZP arms vs PBO. At Wks12 and 24, combined CZP arms showed statistically significant improvements vs PBO in BASDAI, BASFI, and BASMI. Similar improvements were reported with CZP vs PBO in both AS and nr-axSpA pts (Table). Adverse events (AEs) occurred in 70.4% vs 62.6%, serious AEs in 4.7% vs 4.7%, and serious infections in 1.1% vs 0 of CZP (combined dose) pts vs PBO pts, respectively. No deaths, TB or malignancies were reported.

Conclusion:  

CZP effectively and rapidly reduced the signs and symptoms of axSpA, including spinal mobility, with no new safety signals observed. Improvements were similar across CZP dosing regimens, and observed in both AS and nr-axSpA pts.

References:

  1. Rudwaleit M. Ann Rheum Dis. 2009;68(6):770-776

Table: Clinical outcomes at Wk12 and Wk24 for axSpA pts in RAPID-axSpA

Description: AS Clinical 26th June 2012_Table


Disclosure:

R. B. M. Landewé,

UCP Pharma,

5,

UCB Pharma,

2;

M. Rudwaleit,

UCB Pharma,

5;

D. van der Heijde,

UCB Pharma,

5,

UCB Phama,

2,

UCB Pharma,

8;

M. Dougados,

UCB Pharma ,

2,

UCB Pharma,

5;

W. P. Maksymowych,

UCB Pharma,

5,

UCB Pharma,

2,

UCB Pharma,

8;

J. Braun,

UCB Pharma,

2,

UCB Pharma,

5,

UCB Pharma,

8;

A. A. Deodhar,

UCB Pharma,

2,

UCB Pharma,

5;

C. Stach,

UCB Pharma,

3;

B. Hoepken,

UCB Pharma,

3;

G. Coteur,

UCB Pharma,

3;

D. Kielar,

UCB Pharma,

3,

UCB Pharma,

1;

A. Fichtner,

UCB Pharma,

3;

T. Arledge,

UCB Pharma,

3;

J. Sieper,

UCB Pharma,

5,

UCB Pharma,

8.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-certolizumab-pegol-on-signs-and-symptoms-of-ankylosing-spondylitis-and-non-radiographic-axial-spondyloarthritis-24-week-results-of-a-double-blind-randomized-placebo-controlled-phase-3/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology